Analysts' Top 5 Price Targets of March 27, 2025
Reading Time: 2 minutes
Mereo BioPharma [US5894921072]: JPMorgan initiates coverage with an Overweight rating and price target of $7 (180% upside potential) The positive assessment is based on expected data from Phase 3 trials of Setrusumab, a drug for the treatment of Osteogenesis imperfecta. These studies, conducted in partnership with Ultragenyx, have already shown positive and statistically significant results in Phase 2. JPMorgan is confident that the second interim analysis in mid-2025 or the final analysis in the fourth quarter of 2025 will be successful. With...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
